EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel

Michael Krigstein iD, Emily Jude iD, Aleisha Jaffrey iD, Stephen Bye iD, Bin Wang iD, Min Ru Qiu iD, David Ma iD

Annals of Laboratory Medicine · 2025

DOI: 10.3343/alm.2025.0254 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Annals of Laboratory Medicine, 2025. Verfasst von Michael Krigstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pathology, St Vincent's Hospital, Sydney, Australia. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Lymphoma. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Our genomic understanding of lymphomas, a heterogeneous group of neoplasms, has grown exponentially. The latest World Health Organization (WHO) and International Consensus classifications reflect the importance of genetic assessment in the diagnosis and prognostication of and therapeutic decision making in lymphoid neoplasms. To address this clinical need for routinely available and timely testing, we aimed to validate the Ion AmpliSeq Liverpool Lymphoid Network Panel (IALLNP; Thermo Fisher Scientific, Waltham, MA, USA).

Methods

We clinically validated the IALLNP on the Ion Torrent Genexus Sequencer (Thermo Fisher Scientific). The panel detects single-nucleotide variants (SNVs) and insertions/deletions (indels) in 60 clinically relevant genes. The validation set included a commercial control and 54 DNA samples covering the spectrum of clinically aggressive and indolent lymphomas.

Results

After optimizing for poor coverage regions, recurrent artifacts, and false-negative calls, the panel showed good performance in terms of depth of coverage, on-target reads, and uniformity. Its sensitivity for SNVs and indels at a lower limit of detection of 5% variant allele frequency (VAF) was 100%. Specificity in variant-negative samples was 100%, and the mean per-sample number of false-positive variants-which were easily identifiable and excluded upon interrogation of raw data-was 0.4. The panel demonstrated 92.8% reproducibility; however, all nonreproducible variants fell below the 5% VAF analytical threshold.

Conclusions

The IALLNP is an accurate and reproducible next-generation sequencing panel that delivers genetic results for lymphoid neoplasms in a clinically meaningful timeframe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

High-Throughput Nucleotide SequencingLymphomaHumansPolymorphism, Single NucleotideINDEL MutationGene FrequencySequence Analysis, DNA

Stichwörter der Autor:innen

High-throughput nucleotide sequencingLymphomaMolecular pathologyPrecision medicine

Autor:innen und Institutionen

  • Department of Molecular Pathology, St Vincent's Hospital, Sydney, Australia.
  • St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • St Vincent's Centre for Applied Medical Research, Sydney, Australia.

ORCID-Profile: Michael Krigstein, Emily Jude, Aleisha Jaffrey, Stephen Bye, Bin Wang, Min Ru Qiu, David Ma

Zitieren

APA

Krigstein, M., Jude, E., Jaffrey, A., Bye, S., Wang, B., Qiu, M. R., & Ma, D. (2025). Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel. Annals of Laboratory Medicine. https://doi.org/10.3343/alm.2025.0254

Vancouver

Krigstein M, Jude E, Jaffrey A, Bye S, Wang B, Qiu MR, et al. Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel. Annals of Laboratory Medicine. 2025. doi:10.3343/alm.2025.0254

BibTeX
@article{Krigstein2025,
  author = {Krigstein, Michael and Jude, Emily and Jaffrey, Aleisha and Bye, Stephen and Wang, Bin and Qiu, Min Ru and Ma, David},
  title = {Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel},
  journal = {Annals of Laboratory Medicine},
  year = {2025},
  doi = {10.3343/alm.2025.0254}
}
Kostenlos starten →